News | Cardiovascular Ultrasound | March 16, 2017

ASE Releases New Joint Guidelines for Evaluating Valve Regurgitation

Document produced in collaboration with the Society for Cardiovascular Magnetic Resonance recommends integrated approach of ultrasound and MRI to assess complex lesions

valve regurgitation, ASE, new guidelines, imaging, evaluation, SCMR, echocardiography, ultrasound, cardiac MRI

March 16, 2017 — A new document from the American Society of Echocardiography (ASE) provides a comprehensive update to guide clinicians in best practices for assessing all forms of valvular regurgitation.

Valvular regurgitation is a prevalent cardiac disorder in which one or more of the heart’s valves “leak,” often leading to extra burdens on the heart muscle and requiring treatment. While it is difficult to estimate the exact number of people affected by valvular regurgitation, it is very clear that this type of heart disease tends to increase with age; the continuing trend of an aging population worldwide makes guidelines for evaluation of these issues more important than ever, according to ASE.

An update from a popular 2003 guideline publication, the new guideline, “Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance," tackles this complex subject, detailing in its 85 pages and 278 references a compendium of imaging parameters to help clinicians in their assessment of valvular regurgitation. Newly discussed in this edition are the incorporation of three-dimensional echocardiographic imaging, algorithms to facilitate the integration of findings, and the role of cardiac magnetic resonance imaging.

The paper, a joint project between ASE and SCMR, will appear in the April issue of the Journal of the American Society of Echocardiography (JASE), but is available now online. ASE’s Chair of the writing group, William A. Zoghbi, M.D., MACC, FASE of Houston Methodist DeBakey Heart & Vascular Center in Houston, Texas, commented, “With many new advances over the last decade in diagnosis and treatment of valvular regurgitation, there was a clear need to update the original ASE guidelines from 2003. While echocardiography with Doppler is the first-line diagnostic modality to help clinicians in formulating an accurate diagnosis on the causes and severity of the regurgitant valves, an integrative approach of clinical and imaging parameters is strongly recommended to enhance accuracy. These updated guidelines aim first to educate clinicians on how to evaluate these complex lesions, and second, to provide recommendations on assessing the severity of the valvular insufficiency; there is a worldwide need for both, as valvular regurgitation is the most difficult valve lesion to assess.”  

The document outlines in detail the technical considerations and imaging techniques, as well as the value that 3-D echocardiography and cardiac magnetic resonance imaging can add to the diagnostic process. It delves into specific issues with each type of regurgitation, namely mitral regurgitation (MR), aortic regurgitation (AR), tricuspid regurgitation (TR) and pulmonary regurgitation (PR). The document includes 17 tables summarizing techniques and advantages of each modality, as well as 35 figures illustrating various concepts. 

In conjunction with the publication of the guideline document, Zoghbi will conduct a live webinar, including a question and answer section, on April 21 at 9:00 AM Eastern Time. The webinar will be available for free to all ASE members and open to all other clinicians for just $25; registration will open in late March. This webinar, and all ASE-hosted guideline webinars, are available on ASEUniversity.org to facilitate education for those who cannot attend the live webcast.

For more information: www.asecho.org/guidelines

Related Content

AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
News | Left Atrial Appendage (LAA) Occluders| April 25, 2017
AtriCure Inc. announced it has sold more than 100,000 AtriClip Left Atrial Appendage Exclusion System devices worldwide...
Toshiba Showcases Vantage Galan 3T MRI at ISMRM 2017
News | Magnetic Resonance Imaging (MRI)| April 24, 2017
April 24, 2017 — Offering a full range of advanced clinical applications for researchers, Toshiba Medical will demons
Alabama Medical Center First in Southeast to Offer CoreValve Evolut Pro TAVR Device
News | Heart Valve Technology| April 20, 2017
The Structural Heart Program at Princeton Baptist Medical Center, (Birmingham, Ala.) recently became the first center...
Updated AATS Guidelines Help Cardiovascular Surgeons Navigate Challenges of Managing Ischemic Mitral Regurgitation
News | Heart Valve Technology| April 20, 2017
April 20, 2017 — Mitral regurgitation can occur in up to 50 percent of patients with ischemic heart disease and even
3-D-printed Model of Stenotic Intracranial Artery Enables Vessel-Wall MRI Standardization
News | 3-D Printing| April 18, 2017
A collaboration between stroke neurologists at the Medical University of South Carolina (MUSC) and bioengineers at the...

Physicians will need to use a CMS-certified appropriate use criteria (AUC) clinical decision support software that documents the appropriateness of an imaging order to receive full reimbursement for Medicare patients starting Jan. 1, 2018.

Feature | Cardiac Imaging| April 18, 2017 | Dave Fornell
As part of U.S. healthcare reform efforts, starting Jan.
Cardiovascular Institute of the South Upgrades Cardiac Ultrasound With New Toshiba Medical Systems
News | Cardiovascular Ultrasound| April 17, 2017
April 17, 2017 — To bolster its technology and treatment capabilities for coronary and peripheral artery diseases acr
PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device
News | Embolic Protection Devices| April 11, 2017
Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device...
Boston Scientific is buying TAVI valve maker Symetis, which has European approval for its Acurate Neo valve

The Symetis Acurate Neo TAVI valve.

News | Heart Valve Technology| April 11, 2017
April 10, 2017 — Boston Scientific recently announced a $435 million cash deal to acquire Symetis SA, a privately-hel
ASE, EACVI, focused update document, aortic stenosis, AS, echocardiography, new classification scheme
News | Cardiovascular Ultrasound| April 03, 2017
The American Society of Echocardiography (ASE) and the European Association of Cardiovascular Imaging (EACVI) have...
Overlay Init